Real-World Use of Symptomatic Treatments in Early Alzheimer’s Disease

Manuscript Number: 

22-0471R2

Author(s): 
Clive G. Ballard, Maria João Garcia, Sandro Gsteiger, Shona Lang, Regina Leadley, Janine Ross, Elizabeth Vinand

Disclosures

Clive G. Ballard

  • Consulting Fees:
    Advisory board and consultancy fees from Roche, Acadia, TauRx, Otusaka, Lundbeck, NovoNordisk, Suven and Sunovion pharmaceutical companies. Contract research for NovoNordisk, and J and Suven pharmaceutical comapnies

Maria João Garcia

  • Equity:
    F. Hoffmann-La Roche, Ltd
    Sponsors:
    I am a full-time employee at F. Hoffmann-La Roche, Ltd., in Basel, and work as "Global Access Evidence Lead".

Sandro Gsteiger

  • Equity:
    F. Hoffmann-La Roche Ltd. Novartis AG
    Sponsors:
    Employee of F. Hoffmann-La Roche Ltd.

Shona Lang

  • Nothing to Disclose
    Sponsors:
    SHL was funded by Roche to perfrom the systematic review

Regina Leadley

  • Sponsors:
    I am employed by Mtech Access who were commissioned by Roche to conduct and support publication of the systematic literature review.

Janine Ross

  • Sponsors:
    I am employed by Mtech Access who were commissioned by Roche to conduct and support publication of this systematic literature review

Elizabeth Vinand

  • Sponsors:
    I was employed by Mtech Access who were commissioned by Roche to conduct and support publication of the systematic literature review.